Dose Density in Adjuvant Chemotherapy for Breast Cancer

References

• Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352(9132)930–942
   PubMed Web of Science ®Google Scholar
• Hryniuk W. M. The importance of dose intensity in the outcome of chemotherapy. Important Adv. Oncol. 1988; 121–141
   PubMedGoogle Scholar
• Hryniuk W., Frei E., III, Wright F. A. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J. Clin. Oncol. 1998; 16(9)3137–3147, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin. Oncol. 1997; 24(4 Suppl. 10)S10-3–S10-10
   Web of Science ®Google Scholar
• Frei E., III, Canellos G. P. Dose: a critical factor in cancer chemotherapy. Am. J. Med. 1980; 69(4)585–594, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med. 1995; 332(14)901–906, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mayers C., Panzarella T., Tannock I. F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001; 91(17)2246–2257, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Budman D. R., Berry D. A., Cirrincione C. T., Henderson I. C., Wood W. C., Weiss R. B., Ferree C. R., Muss H. B., Green M. R., Norton L., Frei E., III. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The cancer and leukemia group B. J. Natl. Cancer Inst. 1998; 90(16)1205–1211, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Coldman A. J., Goldie J. H. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin. Oncol. 1987; 14(4 Suppl. 4)29–33, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Fisher B., Anderson S., DeCillis A., Dimitrov N., Atkins J. N., Fehrenbacher L., Henry P. H., Romond E. H., Lanier K. S., Davila E., Kardinal C. G., Laufman L., Pierce H. I., Abramson N., Keller A. M., Hamm J. T., Wickerham D. L., Begovic M., Tan-Chiu E., Tian W., Wolmark N. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J. Clin. Oncol. 1999; 17(11)3374–3388, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Henderson I. C., Berry D. A., Demetri G. D., Cirrincione C. T., Goldstein L. J., Martino S., Ingle J. N., Cooper M. R., Hayes D. F., Tkaczuk K. H., Fleming G., Holland J. F., Duggan D. B., Carpenter J. T., Frei E., III, Schilsky R. L., Wood W. C., Muss H. B., Norton L. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 2003; 21(6)976–983, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol. 2001; 19(3)602–611
   PubMed Web of Science ®Google Scholar
• Peters W., Rosner G., Vredenburgh J., Shpall E., Crump M., Richardson P., Marks L., Cirrincione C., Wood W., Henderson I., Hurd D., Norton L. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc. ASCO 1999; 18: 1a
   Google Scholar
• Tallman M. S., Gray R., Robert N. J., LeMaistre C. F., Osborne C. K., Vaughan W. P., Gradishar W. J., Pisansky T. M., Fetting J., Paietta E., Lazarus H. M. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N. Engl. J. Med. 2003; 349(1)17–26, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rodenhuis S., Bontenbal M., Beex L. V., Wagstaff J., Richel D. J., Nooij M. A., Voest E. E., Hupperets P., van Tinteren H., Peterse H. L., TenVergert E. M., de Vries E. G. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N. Engl. J. Med. 2003; 349(1)7–16, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hudis C., Seidman A., Baselga J., Raptis G., Lebwohl D., Gilewski T., Moynahan M., Sklarin N., Fennelly D., Crown J. P., Surbone A., Uhlenhopp M., Riedel E., Yao T. J., Norton L. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J. Clin. Oncol. 1999; 17(1)93–100, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Zambetti M., Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273(7)542–547, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Poole C. J., Earl H. M., Dunn J. A., Hiller L., Bathers S., Spooner D., Grieve R., Agrawall R. K., Foster E., Twelves C. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proc. ASCO 2003; 22: 4
   Google Scholar
• Mamounas E. P., Bryant J., Lembersky B. C., Fisher B., Atkins J. N., Fehrenbacher L., Raich P. C., Yothers G., Soran A., Wolmark N. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc. ASCO 2003; 22: 4
   Google Scholar
• Citron M. L., Berry D. A., Cirrincione C., Hudis C., Winer E. P., Gradishar W. J., Davidson N. E., Martino S., Livingston R., Ingle J. N., Perez E. A., Carpenter J., Hurd D., Holland J. F., Smith B. L., Sartor C. I., Leung E. H., Abrams J., Schilsky R. L., Muss H. B., Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J. Clin. Oncol. 2003; 21(8)1431–1439, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ellis G. K., Livingston R. B., Gralow J. R., Green S. J., Thompson T. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J. Clin. Oncol. 2002; 20(17)3637–3643, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Therasse P., Mauriac L., Welnicka-Jaskiewicz M., Bruning P., Cufer T., Bonnefoi H., Tomiak E., Pritchard K. I., Hamilton A., Piccart M. J. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J. Clin. Oncol. 2003; 21(5)843–850, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J. Clin. Oncol. 1996; 14(6)1885–1894
   PubMed Web of Science ®Google Scholar
• Fumoleau P., Kerbrat P., Romestaing P., Fargeot P., Bremond A., Namer M., Schraub S., Goudier M. J., Mihura J., Monnier A., Clavere P., Serin D., Seffert P., Pourney C., Facchini T., Jacquin J. P., Sztermer J. F., Datchary J., Ramos R., Luporsi E. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study group 01 trial. J. Clin. Oncol. 2003; 21(2)298–305, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sauerbrei W., Bastert G., Bojar H., Beyerle C., Neumann R. L., Schmoor C., Schumacher M. Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: an update based on 10 years' follow-up. The German breast-cancer study group. J. Clin. Oncol. 2000; 18(1)94–101, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Tancini G., Bonadonna G., Valagussa P., Marchini S., Veronesi U. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J. Clin. Oncol. 1983; 1(1)2–10, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Falkson H. C., Gray R., Wolberg W. H., Gillkrist K. W., Harris J. E., Tormey D. C., Falkson G. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J. Clin. Oncol. 1990; 8(4)594–607, [Erratum in J. Clin. Oncol. 1990, 8 (9), 1603]
   Google Scholar
• Jackisch C., Von Minckwitz G., Raab G., Schuette M., Blohmer J. U., Hilfrich J., Gerber B., Costa S., Merkle E., Eidtmann H., Lampe D., DuBois A., Tulusan A. H., Caputo A., Kaufmann M. Primary endpoint analysis of the geparduo study-preoperative chemotherapy (PCT) comparing dose-dense versus sequential adriamycin/docetaxel combination in operable breast cancer (T2-3, N0-2, M0). Br. Cancer Res. Treat. 2002; 76: S50
   Web of Science ®Google Scholar
• Euler U., Dresel V., Buhner M., Volkholz H., Tulusan A. H.T. Dose and time intensified epirubicin/cyclophosphamide (EC) as preoperative treatment in locally advanced breast cancer. Br. Cancer Res. Treat. 2002; 76: S51
   Web of Science ®Google Scholar
• Baldini E., Gardin G., Giannessi P. G., Evangelista G., Roncella M., Prochilo T., Collecchi P., Rosso R., Lionetto R., Bruzzi P., Mosca F., Conte P. F. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann. Oncol. 2003; 14(2)227–232, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Trudeau M. E. Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study. Oncology (Huntingt.) 2001; 5(5 Suppl. 7)7–13
   Google Scholar
• Trudeau M. E., Clemons M., Charbonneau F., Yogendran G., Mehlenbacher A., Pritchard D., Deboer G. Does adjuvant CEF require continuous prophylactic antibiotics (PAbx) to avoid febrile neutropenia (FN)?. Proc. ASCO 2003; 22: 33
   Google Scholar
• Nabholtz J. M., Reese D. M., Lindsay M. A., Riva A. Docetaxel in the treatment of breast cancer: an update on recent studies. Semin. Oncol. 2002; 29(3 Suppl. 12)28–34, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Johnston E., Crawford J., Blackwell S., Bjurstrom T., Lockbaum P., Roskos L., Yang B. B., Gardner S., Miller-Messana M. A., Shoemaker D., Garst J., Schwab G. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J. Clin. Oncol. 2000; 18(13)2522–2528, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Holmes F. A., Jones S. E., O'Shaughnessy J., Vukelja S., George T., Savin M., Richards D., Glaspy J., Meza L., Cohen G., Dhami M., Budman D. R., Hackett J., Brassard M., Yang B. B., Liang B. C. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann. Oncol. 2002; 13(6)903–909, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Holmes F. A., O'Shaughnessy J. A., Vukelja S., Jones S. E., Shogan J., Savin M., Glaspy J., Moore M., Meza L., Wiznitzer I., Neumann T. A., Hill L. R., Liang B. C. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J. Clin. Oncol. 2002; 20(3)727–731, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Green M. D., Koelbl H., Baselga J., Galid A., Guillem V., Gascon P., Siena S., Lalisang R. I., Samonigg H., Clemens M. R., Zani V., Liang B. C., Renwick J., Piccart M. J. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann. Oncol. 2003; 14(1)29–35, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moore T. D., Patel T., Segal M. L., Zangmeister J., Chidiac T. A., Roach R. W., Thompson M. E., Larrimer N. R. A single pegfilgrastim dose per cycle supports dose-dense (q14d) CHOP-R in patients with NHL. Blood 2002; 100(11)571a
   Web of Science ®Google Scholar
• Younes A., Fayad L., Pro B., Romaguera J., Ha C. S., Wilder R. Safety and efficacy of prophylactic pegfilgrastim in patients with hodgkin disease receiving ABVD chemotherapy. Blood 2002; 100(11)171b
   Web of Science ®Google Scholar